Cell-surface receptors guide antisense therapy to mutant KRAS in pancreatic cancer cells
Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer. In a study published in the Journal of Cell Biology (JCB), researchers at the Cancer Research UK Scotland Institute and the U
<p>Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer. In a study published in the Journal of Cell Biology (JCB), researchers at the Cancer Research UK Scotland Institute and the U</p>